REGULATORY INTELLIGENCE·Recall
Dr. Reddy's Glimepiride Tablets Recalled Nationwide Over Tablet Misprint: Supply Chain Implications
Dr. Reddy's Laboratories, Inc. has initiated a Class III recall of 14,425 bottles of Glimepiride Tablets, USP 1mg, across the U.S. due to a tablet misprint. This voluntary action, stemming from its Indian manufacturing arm, highlights critical quality control vulnerabilities. Procurement and regulatory teams must assess supplier quality systems and potential supply disruptions for this essential diabetes medication.
90-Day Activity